Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.

Wengel Kathryn E

Decker Robert J

Schmid Timothy

Wolk Joseph J

Swanson James D.

Broadhurst Vanessa

REED JOHN C

More than 100 prominent organizations have united to promote World Blood Donor Day on June 14, 2026, and Blood Advocacy Week (June 8-12). The initiative highlights that while blood transfusions are needed every 2 seconds in America, less than 3% of eligible Americans donate blood. The campaign theme is 'One Drop of Humanity. Give Blood. Save Lives.' emphasizing the critical need for volunteer blood donors.

Over 100 Organizations Thank America’s Blood Donors on World Blood Donor Day

Legend Biotech announced positive Phase 1 clinical data for LB2501, an investigational in vivo CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. The therapy achieved 100% objective response rate and 83.3% complete response rate at the higher dose level following a single infusion without lymphodepletion, with a favorable safety profile showing no dose-limiting toxicities, serious adverse events, or ICANS.

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Johnson & Johnson announced Phase 3 MonumenTAL-3 study results showing TALVEY® (talquetamab), a GPRC5D bispecific antibody, combined with daratumumab with or without pomalidomide achieved 81.3% progression-free survival and 89.2% overall survival at 24 months in relapsed or refractory multiple myeloma patients, significantly outperforming standard care. The company has submitted a regulatory variation to the EMA for approval of this combination therapy.

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

Johnson & Johnson acquired Firefly Bio for $1 billion to gain access to its Firelink degrader antibody conjugate (DAC) platform, which targets KRAS-driven tumors previously considered 'undruggable.' This acquisition supports J&J's goal of generating $50 billion in annual oncology revenue by 2030, as the antibody drug conjugate market is projected to reach $21-35 billion by 2030-2035.

Johnson & Johnson Just Paid $1 Billion for a Technology That Could Crack One of Cancer's Most "Undruggable" Targets. Why That's Very Good News for Investors.

AbbVie presented 21 clinical presentations on blood cancer therapies at the European Hematology Association Congress, showcasing progress in its oncology portfolio which generated $6.7 billion in 2025 revenue. The company's diversified pipeline across immunology, oncology, and neuroscience is helping offset Humira's patent-driven decline and could support future dividend growth through expanded cash flow.

AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.

Parabilis Medicines raised $670 million in the largest biotech IPO on record, soaring 58% on its first trading day. The company's innovative Helicon platform targets previously 'undruggable' proteins for cancer treatment. While the technology shows promise with lead candidate zolucatetide entering phase 3 trials, the company faces significant losses ($145 million last year) and remains years away from generating revenue, making it suitable only for aggressive investors willing to wait several years.

Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?

Research-driven thematic investor & swing trader. Not financial advice

Subscribe: https://t.co/tRfuPuBAXn

Venu

Teaching traders how to trade with conviction.

Flow Education @ BullFlow https://t.co/iWqwhYLiqb
Live Trading @ Stock Talk Insiders https://t.co/8mopfzD9l9

Danny Naz

USC Pharmacy Alumni, Full Time Investor. My tweets are a general reflection of my Investments and not a recommendation. Please do your own due diligence.

Pharmdca

Retired 2 years ago at 33, Small &Mid cap expert, 80%+ winning ratio in earning prediction, Subscribe for Swing trade signals, Multibagger &Penny stocks. NFA

Johnson & Johnson (JNJ) Stock Price, Analysis & Trade Signals